Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative

Ellis, Kathryn A., Rowe, Christopher C., Villemagne, Victor L., Martins, Ralph N., Masters, Colin L., Salvado, Olivier, Szoeke, Cassandra, Ames, David and AIBL research group (2010) Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative. Alzheimers and Dementia, 6 3: 291-296. doi:10.1016/j.jalz.2010.03.009


Author Ellis, Kathryn A.
Rowe, Christopher C.
Villemagne, Victor L.
Martins, Ralph N.
Masters, Colin L.
Salvado, Olivier
Szoeke, Cassandra
Ames, David
AIBL research group
Title Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative
Journal name Alzheimers and Dementia   Check publisher's open access policy
ISSN 1552-5260
1552-5279
Publication date 2010-05
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.jalz.2010.03.009
Volume 6
Issue 3
Start page 291
End page 296
Total pages 6
Place of publication Philadelphia, PA, United States
Publisher Elsevier
Language eng
Formatted abstract The Australian Imaging Biomarkers and Lifestyle (AIBL) study is a longitudinal study of 1112 volunteers from healthy, mild cognitive impairment, and Alzheimer's disease (AD) populations who can be assessed and followed up for prospective research into aging and AD. AIBL aims to improve understanding of the pathogenesis, early clinical manifestation, and diagnosis of AD, and identify diet and lifestyle factors that influence the development of AD. For AIBL, the magnetic resonance imaging parameters of Alzheimer's Disease Neuroimaging Initiative (ADNI) were adopted and the Pittsuburgh compound B (11C-PiB) positron emission tomography (PET) acquisition and neuropsychological tests were designed to permit comparison and pooling with ADNI data. Differences to ADNI include assessment every 18-months, imaging in 25% (magnetic resonance imaging, 11C-PiB PET but no fluorodeoxyglucose PET), more comprehensive neuropsychological testing, and detailed collection of diet and lifestyle data. AIBL has completed the first 18-month follow-up and is making imaging and clinical data available through the ADNI website. Cross-sectional analysis of baseline data is revealing links between cognition, brain amyloid burden, structural brain changes, biomarkers, and lifestyle.
Keyword Alzheimer's disease
Mild cognitive impairment
Amyloid imaging
Positron emission tomography
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: ERA 2012 Admin Only
School of Information Technology and Electrical Engineering Publications
Centre for Advanced Imaging Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 13 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Access Statistics: 45 Abstract Views  -  Detailed Statistics
Created: Mon, 22 Aug 2011, 18:35:23 EST by System User on behalf of School of Information Technol and Elec Engineering